Core Insights - The World Conference on Lung Cancer (WCLC) 2025 has selected 10 research abstracts from the company, indicating its growing influence in the lung cancer field [1] - The selected studies focus on three core innovative drugs: anti-PD-1 monoclonal antibody Hansizhuang® (Sruvilizumab), anti-EGFR monoclonal antibody HLX07, and the world's first PD-L1 ADC HLX43 entering Phase II clinical trials [1] Group 1: Research Highlights - HLX07 combined with Sruvilizumab and chemotherapy demonstrated a 100% disease control rate and a median progression-free survival (PFS) of 17.4 months in patients with EGFR high-expressing squamous non-small cell lung cancer (NSCLC) [1] - HLX43 showed superior efficacy in specific subgroups, such as EGFR wild-type non-squamous NSCLC, with an overall response rate (ORR) of 47.4%, highlighting both efficacy and safety [1] Group 2: Market Performance - The company has established a differentiated product portfolio in the lung cancer sector, with multiple products approved in nearly 40 countries globally, strengthening its fundamentals [1] - The stock price of the company rose by 2.88% to HKD 76.9, with a total market capitalization of HKD 41.8 billion, reflecting a cumulative increase of nearly 350% since January 23 this year [1]
复宏汉霖三款创新爆品集中亮相WCLC，出击肺癌全类型治疗最前沿